FDA Inspection 1108013 — Recipharm Stockholm AB
The FDA completed an inspection of Recipharm Stockholm AB on June 5, 2019 in Arsta. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- June 5, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Arsta (Sweden)
Additional Details
Mutual Recognition Agreement (MRA)